|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-07S1
|
$37,430
|
$374
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-07
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Validating the prognostic value of EGFR768 in neuroblastoma
|
5R21CA187554-02
|
$204,076
|
$204,076
|
CHAN, EDWARD
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S1
|
$62,500
|
$2,500
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S2
|
$50,000
|
$2,000
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-40
|
$6,231,178
|
$249,247
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Uncovering the anti-apoptotic mechanism of mutated ALK in neuroblastoma
|
5F32CA183566-02
|
$54,194
|
$54,194
|
MOORE, NATHAN
|
DANA-FARBER CANCER INST
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$376,957
|
$33,926
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-03S1
|
$65,036
|
$65,036
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
5R01CA166749-03
|
$318,913
|
$318,913
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-08
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-05S1
|
$114,997
|
$114,997
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-05
|
$363,125
|
$363,125
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-02
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-07
|
$378,479
|
$378,479
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Neuroblastoma with armed T cells
|
5R01CA182526-02
|
$753,575
|
$753,575
|
LUM, LAWRENCE
|
WAYNE STATE UNIVERSITY
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
5U01CA168426-04
|
$1,232,072
|
$1,232,072
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
5R01CA168903-04
|
$345,402
|
$345,402
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$501,603
|
$50,160
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$501,603
|
$100,321
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
1R01CA180692-01A1
|
$623,838
|
$623,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Research Management and Support
|
RMS ES 2015
|
$348,215,937
|
$108,000
|
Unknown, Unknown
|
National Cancer Institute
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-08
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$605,348
|
$363,209
|
Thiele, Carol
|
CCR (NCI)
|
|
Regional Oncology Research Center
|
3P30CA006973-52S1
|
$31,250
|
$313
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-52S2
|
$125,000
|
$1,250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-52S3
|
$185,800
|
$1,858
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-52
|
$6,995,267
|
$69,953
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
5R01CA109234-10
|
$420,010
|
$105,003
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy
|
5R01CA154561-05
|
$51,736
|
$51,736
|
SEO, YOUNGHO
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Prenatal stress and neuroblastoma development - is there a link?
|
1R21CA198698-01
|
$202,928
|
$202,928
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-08
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
|
5R01CA168699-03
|
$1
|
$1
|
KANG, MIN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Pediatric Preclinical Testing Consortium
|
1U01CA199287-01
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,191,605
|
$159,580
|
Merchant, Melinda
|
CCR (NCI)
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$325,957
|
$293,361
|
Thiele, Carol
|
CCR (NCI)
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
4R00CA178189-03
|
$249,000
|
$249,000
|
ZHU, SHIZHEN
|
MAYO CLINIC ROCHESTER
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-03
|
$324,006
|
$324,006
|
DUBOIS, STEVEN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
1R01CA197964-01
|
$350,628
|
$175,314
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
3U54CA121852-10S1
|
$100,000
|
$8,000
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
MYCN-induced calcium and magnesium signaling regulates Neuroblastoma progression
|
5K01CA154758-04
|
$134,922
|
$134,922
|
KOOMOA, DANA-LYNN
|
UNIVERSITY OF HAWAII AT HILO
|
|
MYC--Transcription and Apoptosis
|
5R01CA051497-24
|
$394,000
|
$197,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Murine Neuroblastoma Models for Preclinical Therapeutics
|
5R01CA102321-12
|
$261,089
|
$261,089
|
WEISS, WILLIAM
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-02
|
$671,686
|
$671,686
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
1R21CA181417-01A1
|
$184,515
|
$92,258
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
|
Methods for genomic data with graphical structures
|
5R01CA127334-08
|
$293,687
|
$146,844
|
LEE, HONGZHE
|
UNIVERSITY OF PENNSYLVANIA
|
|
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
|
1R41CA192656-01
|
$209,001
|
$209,001
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
5R01CA116548-10
|
$234,457
|
$234,457
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Large-scale Genetic Analyses of Human Cancer
|
5R01CA121113-09
|
$279,212
|
$13,961
|
VELCULESCU, VICTOR
|
JOHNS HOPKINS UNIVERSITY
|
|
Investigating the tumor suppressive functions of the miR-34 family of microRNAs
|
5F31CA168356-03
|
$43,120
|
$21,560
|
CONCEPCION, CARLA
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
Total relevant funding to Neuroblastoma for this search: $19,155,625
|